Christopher Colecchi is the Managing Director of Broadview Ventures. Chris leads the Broadview investment team and operations, and coordinates the activities of Broadview’s Strategic Advisory Board.
Previously, Chris was the Vice President for Research Ventures and Licensing at Partners Healthcare – an integrated health system founded by the Harvard-affiliated Brigham and Women’s Hospital and Massachusetts General Hospital. Chris led business development, technology transfer, and commercialization activities at Partners and managed efforts to establish strategic alliances with the life sciences industries. He also created the Partners Innovation Fund – a venture capital fund that makes investments in early stage companies emerging from Partners hospitals.
Earlier in his career, Chris was the Director of Clinical Trials and Industrial Relations for the Massachusetts General Hospital and Director of Clinical Monitoring for a clinical research organization at which he oversaw the set-up and management of multi-center, industry-sponsored clinical trials at several hundred sites throughout the U.S. and Canada. Within these roles, Chris worked directly with most of the major international pharmaceutical and biotechnology companies as well as many in the device arena.
Chris currently serves on the boards of Aggamin, Cardero, CellAegis, EP Sciences, and Ground Fluor Pharma. He previously served on the boards of CardiAQ (Acquired by Edwards Life Sciences), miRagen (NSDQ: MGEN) and InfoBionic.
Outside of Broadview, Chris serves as an advisory board member for the University of Massachusetts School of Public Health and Health Sciences. He is a board member of the Massachusetts Association for Mental Health and the Institute for Cardiovascular Research and Science founded by the Royal Brompton and the Liverpool Heart and Chest Hospitals.
Chris holds a B.A. from Holy Cross College and an M.P.H. from the University of Massachusetts School of Public Health. He lives in Andover, Massachusetts with his wife, Kathy, and three children, Benjamin, Talia and Joseph.
Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures.
Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.
Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercial strategy and competitive strategic planning for BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA.
Maria currently serves on the boards of Alleviant, Adient, Aria CV, AtaCor, FineHeart, Vascular Graft Solutions and Vectorious, and previously served on the boards of Lyra Therapeutics (NSDQ:LYRA), Apama (acquired), Remedy (acquired), and Capricor (NASDAQ:CAPR).
In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.
Christopher de Souza, PhD, MBA, is a Director at Broadview Ventures. He brings to this role over 30 years of experience in cardiovascular and metabolic related academic research, biopharmaceutical R&D, corporate strategy and business development.
Christopher started his pharmaceutical career at Novartis as a senior scientist in the Metabolic and Cardiovascular Diseases group and then as Director of Strategic Alliances with responsibilities for therapeutic area strategy, business development and alliance management. After Novartis, Christopher was Vice President of Business Development at SkyePharma US Inc., a drug delivery company, where he was responsible for out-licensing the company’s clinical assets and drug delivery technologies.
Christopher received a Masters in zoology from the University of Bombay, a PhD in physiology from Louisiana State University and an MBA from Rutgers University. He completed his post-doctoral training at The Upjohn Company and the Joslin Diabetes Center/Harvard Medical School.
Christopher currently serves on the boards of Acesion, Gila Therapeutics, Mellitus and Pulmokine and previously served on the boards of Allosteros, CellAegis, DecImmune, Herantis, NuPulse, Provasculon and Ventrinova.
Outside of Broadview Ventures, Christopher serves on the board of MassBio and on the grant review committees of the British Heart Foundation and NIH/NHLBI.
Tom Needham, MBA, is a Director and Head of the Biopharmaceuticals practice at Broadview Ventures.
Tom shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.
Tom comes to Broadview with 25 years of experience in venture capital, business development, corporate strategy, and executive management responsibilities in public and private life science companies. Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (Nasdaq: MACK) and Senior Vice President, Business Development at C4 Therapeutics.
Prior to C4T, Tom spent 13 years as a venture capital investor, most recently as a Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Prior to Synthesis, Tom was a Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, including GPC Biotech (FSE: GPC/Nasdaq: GPCB) and Mitotix, Inc. (acquired by GPC Biotech), where he led the negotiation and closing of a number of strategic transactions, including industry partnerships with global pharmaceutical companies, R&D collaborations, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.
Tom currently holds board roles at Kantum Pharma, Renovacor, and Antag Therapeutics. Tom’s venture investment experience also includes working on Epirium Bio (fka Cardero Therapeutics), Astex Pharmaceuticals (Nasdaq: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (Nasdaq: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and as an active deal team member on the IPO and exit from Aegerion Pharmaceuticals (Nasdaq: AEGR).
Daniel Gottlieb, MBA, is an Associate Director at Broadview Ventures.
Daniel shares responsibility for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.
Daniel has 20 years of experience at medical device and biotechnology companies in corporate and business development, corporate venture capital, marketing, and strategy. Previously, Daniel was a member of the leadership team at Proteon Therapeutics, most recently as Vice President, Corporate Development. Daniel led Proteon’s business development, strategic marketing, and corporate development activities as the company progressed from a Series A startup through multiple private financings, a successful IPO, and completion of Phase 3 clinical studies. Prior to Proteon, Daniel was a strategic marketing manager in Abbott Vascular’s endovascular business unit, where he led the team developing next generation devices for peripheral artery disease. Prior to that, Daniel was at Guidant Corporation, primarily as a member of Guidant Compass, the company’s corporate venture capital, business development, and corporate strategy group. As a member of the Compass team, Daniel led investments in early stage cardiovascular device companies, focusing on coronary and peripheral revascularization, cardiac rhythm management, heart failure monitoring, and cardiac surgery.
Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth College.
Hewmun Lau, MBA, is a Principal at Broadview Ventures.
Hewmun shares responsibility for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.
Hewmun comes to Broadview with 10 years of life science experience across business development, commercial operations, consulting and R&D. Previously, Hewmun was at Merrimack Pharmaceuticals where she held several roles with increasing responsibility. She was most recently Director of Corporate Development where she led the company’s business development activities. Her prior positions within Merrimack include Associate Director of New Product Planning and Senior Manager of Commercial Analytics where she supported the launch of Merrimack’s first marketed drug. Before Merrimack, Hewmun was a Senior Consultant at Navigant Consulting’s Life Sciences Practice. At Navigant, she worked on engagements involving big pharma and emerging biotech companies across all therapeutic areas. Client engagements ranged from commercial opportunity assessment to launch strategy and product lifecycle management. Hewmun began her career in biomedical research including lab research positions at Millennium Pharmaceuticals and McLean Hospital.
Hewmun holds a B.S. from Brandeis University, an MBA from MIT’s Sloan School of Management and a M.S. from the Harvard-MIT Program in Health Sciences and Technology.
Nichole Neal, MBA is the Director of Operations at Broadview Ventures. Nichole brings more than 10 years of experience in operations management and administration.
Nichole manages the business operations along with the triage of incoming investment opportunities. She also serves as the office liaison, spearheads the meeting and event planning, and supports the investment team in their day-to-day operations.
Prior to joining Broadview Ventures, Nichole was the program administrator for both the Cardiovascular Program (Heart Center) and the Medicine Intensive Care Unit at Boston Children’s Hospital. There, Nichole worked alongside the Vice President of Nursing and Critical Care Services, and was responsible for overseeing business operations, managing and coaching administrative staff, developing and executing best practices, and improving processes and compliance in support of the hospital’s mission.
Nichole earned a Bachelor’s Degree in Science in Healthcare Management and Policy at the University of New Hampshire and a Master’s Degree (MBA) in Business and Healthcare Management from the University of Phoenix.
David Milan, MD is the Chief Scientific Officer of the Leducq organization.
David’s most recent position was at the Massachusetts General Hospital and Harvard Medical School where he was Assistant Professor of Medicine, and worked both clinically and conducted research in the field of cardiac Electrophysiology. He received his undergraduate degree from Stanford University in Chemistry and performed his medical training at Harvard Medical School. His residency in Internal Medicine was at the Brigham and Women’s Hospital followed by fellowships in Cardiology and Cardiac Electrophysiology at Massachusetts General Hospital. His research focus at MGH was on the molecular basis of cardiac arrhythmias using zebrafish and stem cell models, as well as studies of valvular heart disease.
Benjamin Kreitman broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.
Prior to joining Broadview, Benjamin was a Consultant at Monitor Deloitte, the strategy management consulting arm of Deloitte Consulting, LLP. At Monitor Deloitte, Benjamin worked alongside senior executives on a variety of engagements including commercial strategy development for biotechnology startups as well as global pharmaceutical and medical device manufacturers, and corporate development and investment due diligence across a number of industries.
Benjamin earned undergraduate degrees in Biological Sciences and Financial Economics Magna Cum Laude from Columbia University.
Adam Cohen broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.
Prior to joining Broadview, Adam was a strategy consultant at Health Advances, where he specialized in life sciences with a focus on cardiovascular technologies. At Health Advances, Adam led engagements in investment opportunity due diligence for strategic and financial investors as well as in commercial strategy for a broad range of BioPharma and Medtech clients. Adam also brings cardiovascular device engineering experience from prior roles at CVRx and Cardiac Solutions LLC.
Adam earned a master’s degree in Biomedical Engineering from Duke University as well as undergraduate degrees in Engineering Science and Economics with High Distinction from the University of Virginia.
Strategic Advisory Board
EUGENE BRAUNWALD, M.D. is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and the founding Chair of the TIMI Study Group at the Brigham and Women’s Hospital.
Dr. Braunwald received his medical training at New York University and completed his Medical Residency at the Johns Hopkins Hospital. He served as the first Chief of the Cardiology Branch and as Clinical Director of the National Heart, Lung and Blood Institute, founding Chairman of the Department of Medicine at the University of California, San Diego. From 1972 to 1996 he was Chairman of the Department of Medicine at the Brigham and Women’s Hospital. He was a founding trustee and Chief Academic Officer of Partners HealthCare System.
Dr. Braunwald’s first major paper was published in Circulation Research in July 1954, and he has been a major force in cardiology in the past sixty years. His early work focused on the control of ventricular function and he was the first to measure both left ventricular ejection fraction and left ventricular dp/dt in patients. His group showed the first neurohumoral defect in human heart failure, defined the pathophysiology of hypertrophic cardiomyopathy and demonstrated salvage of ischemic myocardium following coronary occlusion. They defined myocardial stunning and ventricular remodeling following myocardial infarction. For the past 35 years, he and his colleagues at the TIMI Study Group demonstrated improved patient survival with a patent coronary artery which led to the widely accepted “open artery hypotheses.” They were the first to show the benefit of preventing adverse remodeling of the infarcted ventricle with ACE inhibition. In the PROVE-IT TIMI 22 Trial, in 2004, they demonstrated the benefit of more intensive reduction of LDL in high risk coronary artery patients, which has changed practice guidelines and will favorably affect the lives of millions.
Dr. Braunwald has been an editor of Harrison’s Principles of Internal Medicine for 12 editions, and the founding editor of Heart Disease, now in its 11th Edition, the most influential textbooks in their fields.
Science Watch listed Dr. Braunwald as the most frequently cited author in Cardiology; he has an H index of 227. Based on his contributions, Dr. Braunwald has received numerous honors and awards including the Distinguished Scientist and Lifetime Achievement Awards of the American College of Cardiology, Research Achievement, and Herrick Awards of the American Heart Association, the Gold Medal of the European Society of Cardiology. He received an honorary Doctor of Science from the University of Oxford and is the recipient of honorary doctorates from twenty three other distinguished universities on three continents. The American College of Cardiology has established an annual lecture in his name. The European Society of Cardiology, Heart Failure Association has established an annual lecture in his name. Dr. Braunwald was the first cardiologist elected to the National Academy of Sciences of the United States. The living Nobel Prize winners in medicine voted Dr. Braunwald as “the person who has contributed the most to cardiology in recent years”.
Professor Kim Fox
Kim Fox, MD is Professor of Clinical Cardiology and was previously Head of the National Heart and Lung Institute at Imperial College London. He is also Diana, Princess of Wales Chair in Cardiovascular Medicine and Science and Consultant Cardiologist at the Royal Brompton Hospital. Professor Fox was a non-Executive Director of the Royal Brompton and Harefield NHS Foundation Trust and is a Trustee of the Institute of Cardiovascular Medicine and Science, Magdi Yacoub Institute, and National Heart and Lung Institute Foundation.
He was President of the European Society of Cardiology 2006-2008, having previously been Treasurer and Secretary. He was Associate Editor of the British Heart Journal in 1985-1994 and Editor in Chief of the European Heart Journal 1994-2002. He has previously served as a member of the British Heart Foundation Education Committee (chair), Council and Executive Committee as well as the British Cardiac Society’s Council and Medical Practice Committee (chair).
Professor Fox has published over 500 papers in leading scientific journals. His expertise is in the understanding, investigation and treatment of angina; in particular the role of heart rate in the pathophysiology of myocardial ischaemia and infarction. He has played a major role in many important international clinical trials (EUROPA, IONA, BEAUTIFUL, HPS, ASCOT, SEARCH, PERFORM, SIGNIFY, etc) that have changed the treatment of this condition. He chaired the Task Force producing the European Angina Guidelines and chaired the committee responsible for the audit for the management of these patients in Europe.
Professor Fox has given plenary lectures to National Societies all over the world. He has given the “Finlayson Lecture” to the Royal College of Surgeons in Glasgow, the “St Cyres Lecture” to the British Cardiac Society, the “Andrea Cissalpino Lecture” to the Italian Cardiac Society and the “Stokes Lecture” to the Irish Cardiac Society. Professor Fox has been elected an honorary member of the French Cardiac Society and Japanese Circulation Society for his services to cardiology. He has been awarded the Mackenzie Medal of the British Cardiovascular Society, the Gold Medal of the European Society of Cardiology, the Chazov Medal of the Russian Federation of Cardiology and the Stokes Medal of the Irish Cardiac Society.
Thomas Hughes, PhD
President and Chief Executive Officer, Navitor Pharmaceuticals
Dr. Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Prior to joining Navitor, Dr. Hughes served as President and Chief Scientific Officer of Zafgen and previously led Zafgen as CEO from 2008 to 2017. During this time, Dr. Hughes established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Dr. Hughes held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Dr. Hughes currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., is an advisor to Atlas Venture, and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and Nimbus Therapeutics.
Dr. Hughes holds a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in zoology from Virginia Polytechnic Institute & State University and a B.A. in biology from Franklin and Marshall College
Costantino Iadecola, M.D.
Anne Parrish Titzell Professor of Neurology
Director and Chair, Feil Family Brain and Mind Research Institute
Weill Cornell Medical College, New York
Dr. Iadecola is a clinician-scientist who is an internationally recognized expert in the field of cerebrovascular diseases and dementia. Dr. Iadecola received an MD degree from the University of Rome, Italy, and completed Neurology Residencies both at the University of Rome and at New York Hospital-Cornell Medical Center, New York, NY.
After completing his training, Dr. Iadecola joined the Department of Neurology of the University of Minnesota, where he rose through the academic ranks serving as Professor and Vice-Chair for Research. In 2001, Dr. Iadecola was recruited back to Cornell as the G. C. Cotzias Distinguished Professor of Neurology and Neuroscience, and Director of the Division of Neurobiology. In 2012 Dr. Iadecola was appointed Anne Parrish Titzell Professor of Neurology and Director of the Feil Family Brain and Mind Research Institute, a new Department at Weill Cornell focused on basic and translational neuroscience research.
Dr. Iadecola’s research focuses on the basic mechanisms of neurovascular function and on the cellular and molecular alterations underlying ischemic brain injury, neurodegeneration and cognitive impairment. A pioneer in establishing the concept of Neurovascular Unit, Dr. Iadecola has championed the involvement of neurovascular dysfunction in neurodegenerative diseases, and the role of innate immunity and the microbiome in ischemic brain injury. He is active in several national and international research organizations and funding agencies, including the NIH, the American Heart Association (AHA) and the Alzheimer’s Association. He has been President (Chair) of the Scientific Advisory Committee of the Fondation Leducq and is an advisor to the several research consortia in the US and Europe. Dr. Iadecola has served as Editor or Editorial Board member for a number of journals including: Stroke, Journal of Neuroscience, Circulation research, and the Annals of Neurology.
Dr. Iadecola has received the McHenry Award from the American Academy of Neurology, the Louis Sklarow Memorial Award, the Established Investigator Award (AHA), two Jacob Javits Awards from NINDS/NIH (1999, 2015), the Willis Award, the highest honor in stroke research bestowed by the AHA, and the Zenith Fellow Award from the Alzheimer’s Association in recognition of his work on the role of vascular factors in Alzheimer’s dementia. In 2015 Dr. Iadecola was awarded the Excellence Award in Hypertension Research by the Hypertension Council of the AHA for his studies on the role of high blood pressure in promoting both vascular cognitive impairment and Alzheimer’s disease. In 2015 he was elected to the Association of American Physicians and in 2019 was honored as Distinguished Scientist by the AHA. He is the principal investigator of several NIH grants. Since 2018, Clarivate Analytics (Web of Science) has listed Dr. Iadecola as one of world’s “Highly Cited Researchers” for ranking in the top one percent of the most-cited authors in the field of neuroscience and behavioral sciences.
Argeris “Jerry” Karabelas, PhD
Dr. Karabelas is a Partner at Care Capital, LLC, a life sciences venture firm. He is also a member of the board of RegenXbio, a publicly traded gene therapy company; a member of the board of Bausch Health Companies, Inc., a public company; and a member of the board of Braeburn Pharmaceuticals, a privately held company focusing on treatments for addiction and pain. Dr. Karabelas is also a member of the Strategic Advisory Board of Broadview Ventures.
Previous to these positions, Dr. Karabelas founded the Novartis Bio Venture Fund; was the CEO of Worldwide Pharmaceuticals, Head of all Healthcare Businesses and member of the Executive Committee at Novartis, AG; was Executive Vice President of Pharmaceuticals at SmithKline Beecham, Chairman of the Pharmaceutical Executive and Development Committees, and a member of the Executive Committee of SmithKline Beecham. Previous to these senior executive positions, Dr. Karabelas had a typically progressive career in pharmaceutical sales and marketing at SmithKline and French. He was also a Professor of Pharmacokinetics.
Dr. Karabelas has founded several companies: CytoTherapeutics, Inc., Vanda Pharmaceuticals Inc., and Minerva Pharmaceuticals. He is former Chairman of Human Genome Sciences, Vanda Pharmaceuticals Inc., Renovo, NitroMed, Inc., and SkyePharma plc.
Dr. Karabelas holds a Ph.D. in Pharmaceutical Sciences and Pharmacokinetics from the Massachusetts College of Pharmacy and a Bachelor of Sciences in BioChemistry from the University of New Hampshire.
Martín Landaluce is the President of the Fondation Leducq Board of Directors, where he has served as a member for over 24 years. He oversees the investment and spending policies of the Leducq Trust, and with David Tancredi represents the trust on the Broadview Board of Directors. Mr. Landaluce grew up and was educated in Madrid, and is currently a resident of London.
Joseph Loscalzo, M.D., Ph.D.
Hersey Professor of the Theory and Practice of Medicine
Harvard Medical School
Chairman, Department of Medicine
Brigham and Women’s Hospital
Dr. Joseph Loscalzo is Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine.
After completing his training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005.
Dr. Loscalzo is recognized as an outstanding cardiovascular scientist, clinician, and teacher. He has received many awards, including the Clinician-Scientist Award, the Distinguished Scientist Award, the Research Achievement Award, and the Paul Dudley White Award from the American Heart Association; a Research Career Development Award, a Specialized Center of Research in Ischemic Heart Disease Award, and a MERIT Award from the National Institutes of Health; the George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital, the Educator of the Year Award in Clinical Medicine from Boston University, and the William Silen Lifetime Achievement in Mentorship Award from Harvard Medical School; the Glaxo Cardiovascular Research Award, and the Outstanding Investigator Prize from the International Society for Heart Research; election to fellowship in the American Association for the Advancement of Science, and in the American Academy of Arts and Sciences; and election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. Castle Connolly has named him one of America’s Top Doctors. He served as an associate editor of the New England Journal of Medicine for nine years, Chair of the Cardiovascular Board of the American Board of Internal Medicine, Chair of the Research Committee of the American Heart Association, Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in the Cardiovascular Sciences, and Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. He is currently Director of the NIH-funded Center for Accelerated Innovation (the Boston Biomedical Innovation Center), the NIH-funded Harvard Undiagnosed Disease Network program. He is also former Editor-in-Chief of Circulation, and a current senior editor of Harrison’s Principles of Internal Medicine.
Dr. Loscalzo has been a visiting professor at many institutions, holds two honorary degrees, has authored or co-authored more than 1,000 scientific publications, has authored or edited 51 books, and holds 32 patents for his work in the field of nitric oxide and redox biology. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, atherosclerosis, and, more recently, systems biology over the past thirty years. His most recent work has established the field of network medicine, a paradigm-changing discipline that seeks to re-define disease and therapeutics from an integrated perspective using systems biology and network science.
Eric A. Rose, MD is a member and former chairman of the Broadview Strategic Advisory Board. He is the inaugural chairman of the Longview Strategic Advisory Board. He is an academic physician and entrepreneur with interests in drug discovery, biodefense, clinical evaluative research and health policy. He is the Chairman of Siga Technologies, Inc., the developer of an orally bioavailable smallpox anti-viral drug which has been added to the US Strategic National Stockpile.
He is a Professor of Population Health Science, Cardiac Surgery, Surgery, and Cardiology at the Mount Sinai School of Medicine since 2008. From 1994 through 2007, he served as Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he held a distinguished professorship.
An accomplished heart surgeon, researcher and entrepreneur, Dr. Rose grew one of the nation’s premier departments of surgery while managing, investigating and developing complex medical technologies ranging from heart transplantation and novel approaches to Alzheimer’s disease to bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research.
Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. Siga has received more than $100 million in federal research support and more than $1 billion in federal procurement of its smallpox antiviral since he joined the company, He received both his undergraduate and medical degrees from Columbia University.
David Tancredi, MD, PhD
David Tancredi is the Executive Director of the Leducq Foundation, and President of Broadview Ventures. With Martín Landaluce, he serves on the board of the Leducq Trust. A graduate of Harvard Medical School, Dr. Tancredi completed a residency in emergency medicine at the University of Cincinnati before obtaining a Ph.D. in sociocultural anthropology from the University of Chicago.
Hugh Watkins is the Radcliffe Professor of Medicine and Head of the Radcliffe Department of Medicine at the University of Oxford and Honorary Consultant in Cardiology at the John Radcliffe Hospital. From 1998-2005 he was Programme Director of the Wellcome Trust Cardiovascular Research Initiative at the University of Oxford. He has been the Director of the British Heart Foundation Centre of Research Excellence at Oxford since its inception in 2008. Professor Watkins was a member of the Fondation Leducq Scientific Advisory Committee from 2011 to 2017. Honors and distinctions have included the Thomas Lewis Lecture, British Cardiac Society, 2004, the Paul Dudley White Lecture, American Heart Association, 2011 and the Mackenzie Medal of the British Cardiovascular Society in 2018.
Professor Watkins has made a series of major contributions to the understanding of the molecular genetic basis of cardiovascular disease, using genetic approaches to define disease mechanisms and to improve diagnosis and treatment of patients and families with inherited diseases. He works on both rare inherited diseases, such as cardiomyopathy, where genetic advances now underpin diagnosis and new approaches to therapy, and common diseases such as Coronary Artery Disease where the goal is to use newly identified common genetic variants to define novel therapeutic targets. Through both his Mendelian and complex trait genetics work, Professor Watkins has defined some of the most medically important disease genes affecting the cardiovascular system. He has built up a specialist clinical and laboratory genetic service in Inherited Cardiac Conditions in Oxford which has a national and international profile and he has authored clinical and genetic testing guidelines for US and European societies. He has an h-index of over 100 and is a Web of Science Highly Cited Researcher.
In 2017 he was elected a Fellow of the Royal Society. He is also a Fellow of the Academy of Medical Sciences.
Annabel Chen-Tournoux, MD, is an advisor to Broadview Ventures, where she was formerly a member of the operations team.
Forcht (Teo) Dagi, MD, MPH, MBA, DMedSc, DHC, FRCSEd is a neurosurgeon and neuro-intensivist, a veteran venture capitalist and board director with extensive international experience in public service. He has helped raise over $700 million in funds for portfolio companies and venture capital funds and has more than 15 years of successful experience in founding, managing and exiting companies in health care services and in the life sciences. He has operating experience in healthcare services, healthcare information technology and the biomedical sector, and he has served on boards of directors of publicly traded and privately held companies including. His portfolio has included AtheroGenics, Inc (Nasdaq: AGIX); Inhibitex, Inc. (Nasdaq: INHX, acquired by Bristol-Myers-Squibb); Synageva, Inc. (acquired by Alexion); Trivirix, Inc. (acquired by Nortel); Encelle, Inc. (acquired by Pioneer Surgical); Teladoc (NYSE: TDOC); and Merix Biosciences (now Argos Therapeutics, Nasdaq: ARGS). He has also chaired or served on the scientific advisory boards of Dupont Pharma, Lundbeck, the Royal Bank of Canada and other private and publicly listed companies.
Dr. Dagi serves as Distinguished Scholar and Professor at Queen’s University Belfast, Northern Ireland (UK), and a Scholar in the Academy at Harvard Medical School. He is past chair of the International Advisory Panel of the Queen’s School of Medicine. He is immediate past chair, and a Director of the Committee on Perioperative Care of the American College of Surgery the Council for Surgical and Perioperative Safety and the Anesthesia Patient Safety Foundation. He has lectured in the Harvard Business School on healthcare innovation and in the Biomedical Entrepreneurship Program at the Harvard-MIT Program in Health Sciences and Technology. He is Director of Life Sciences at Anglo Scientific at the Royal Institution of Great Britain.
Dr. Dagi received an AB from Columbia University, his MD and MPH degrees from Johns Hopkins, and an MBA from the Wharton School. He was named the Joseph P. Kennedy, Jr., Fellow at Harvard, from which he also received a MTS (jurisprudence). He trained at the Massachusetts General Hospital and the Neurosurgical Unit of the Guy’s, Maudsley and King’s College Hospitals in London, and was a Mendeleyeff Travelling Fellow and a Neuroresearch Foundation Fellow. He worked at the MGH Limbic Diencephalic Laboratory on neuromodulation, and at the NIH on PET scanning under Dr. Louis Sokoloff in the Laboratory for Cerebral Metabolism. He was appointed to the Reserve Council of the United States, and served as a neurosurgeon at the Walter Reed Army Medical Center, combat neurosurgeon and flight surgeon, and faculty in the John Fitzgerald Kennedy School for Special Warfare and the Uniformed Services University of the Health Sciences. He is a fellow of the American Association of Neurological Surgeons, the American College of Surgeons, for which he serves as a spokesman, and, by election, to the College of Critical Care Medicine, reserved for the highest 5% of practitioners in the field.
Dr. Dagi was President of the Georgia Neurosurgical Society, Director of the Georgia Biomedical Association, Founding Director of the Southeast Life Sciences Investor Association, Director of the Medical Development Group in Massachusetts and a Director of the American Association of Neurological Surgeons. He serves as an overseer of the Beth Israel Deaconess Medical Center in Boston and sits on the Research Oversight Committee. Among other distinctions, he has been awarded the US Humanitarian Service Medal, and a DMedSc from Queen’s University Belfast, and a DHC from the Kaunas Technical University in Lithuania for contributions to medicine and public service. He was named the Sir Thomas and Edith Dixon Medalist for 2012 and was named to an ad hominem Fellowship in the Royal College of Surgeons Edinburgh in 2013. In 2015 he was the Distinguished Lecturer in the Space 4 Biomedicine Program of the National Space Biomedical Research Institute (NSBRI) and the Baylor College of Medicine Center for Space Medicine. In 2016 he was named to the advisory board of CURAM, the Science Foundation Ireland Centre for Research in Medical Devices in Galway, Ireland. He is an editor of Neurosurgery, the Journal of Clinical Ethics, and Numanities, and has authored or co-authored over 175 articles and authored or edited several books.
Marc Semigran, MD joined MyoKardia as chief medical officer in December, 2016. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. He has published more than 150 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. Dr. Semigran is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.
Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.